She shares her results on a new drug’s effect on vasomotor symptoms
At the annual North American Menopause Society (NAMS) meeting in September 2019, news was presented on the development of a new hormonal oral medication, fezolinetant, for women with moderate to severe vasomotor symptoms of menopause (VSM).
Currently, the most commonly used drugs to control VSM should be avoided by women who have estrogen receptor-positive cancer, leg or lung blood clots, stroke, liver disease, or unexplained vaginal bleeding.
In phase 2 of the trial on fezolinetant, Dr. Nanette Santoro reported a significant reduction in the frequency of VSM, even while taking into consideration and adjusting for the placebo effect.
NAMS is excited about the new menopause medication and is hopeful that it will come to market. The phase 3 clinical trial is underway.